ANI Pharmaceuticals (NASDAQ:ANIP) Given "Buy" Rating at HC Wainwright

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report)'s stock had its "buy" rating restated by equities research analysts at HC Wainwright in a research note issued on Monday,Benzinga reports. They currently have a $94.00 price target on the specialty pharmaceutical company's stock. HC Wainwright's price objective suggests a potential upside of 46.28% from the company's previous close.

A number of other analysts have also commented on ANIP. Guggenheim increased their price objective on ANI Pharmaceuticals from $84.00 to $86.00 and gave the company a "buy" rating in a research note on Wednesday, March 5th. Jefferies Financial Group assumed coverage on shares of ANI Pharmaceuticals in a report on Friday, March 14th. They set a "buy" rating and a $80.00 price target for the company. JPMorgan Chase & Co. assumed coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, March 12th. They set an "overweight" rating and a $85.00 price objective on the stock. Leerink Partnrs upgraded ANI Pharmaceuticals to a "strong-buy" rating in a report on Wednesday, December 11th. Finally, Leerink Partners began coverage on ANI Pharmaceuticals in a report on Wednesday, December 11th. They set an "outperform" rating and a $80.00 price objective on the stock. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $79.75.

Remove Ads

ANI Pharmaceuticals Stock Performance

NASDAQ:ANIP traded down $0.09 during midday trading on Monday, reaching $64.26. The stock had a trading volume of 519,758 shares, compared to its average volume of 240,612. The stock has a market cap of $1.40 billion, a P/E ratio of -116.84 and a beta of 0.63. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. ANI Pharmaceuticals has a 12-month low of $52.50 and a 12-month high of $70.81. The firm has a fifty day simple moving average of $59.21 and a two-hundred day simple moving average of $58.16.

Insider Buying and Selling at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, VP Meredith Cook sold 400 shares of the company's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $63.33, for a total value of $25,332.00. Following the completion of the sale, the vice president now directly owns 80,545 shares in the company, valued at $5,100,914.85. This represents a 0.49 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Krista Davis sold 1,000 shares of ANI Pharmaceuticals stock in a transaction on Friday, February 21st. The shares were sold at an average price of $60.20, for a total value of $60,200.00. Following the transaction, the senior vice president now owns 68,624 shares in the company, valued at approximately $4,131,164.80. This trade represents a 1.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 3,200 shares of company stock valued at $191,776. Company insiders own 12.70% of the company's stock.

Hedge Funds Weigh In On ANI Pharmaceuticals

Several large investors have recently made changes to their positions in the business. US Bancorp DE lifted its stake in ANI Pharmaceuticals by 842.9% during the fourth quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company's stock valued at $33,000 after purchasing an additional 531 shares during the last quarter. KBC Group NV lifted its position in shares of ANI Pharmaceuticals by 89.2% during the 4th quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company's stock valued at $70,000 after acquiring an additional 600 shares during the last quarter. KLP Kapitalforvaltning AS bought a new stake in shares of ANI Pharmaceuticals during the 4th quarter worth $166,000. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of ANI Pharmaceuticals by 24.2% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company's stock worth $177,000 after acquiring an additional 579 shares during the last quarter. Finally, Rafferty Asset Management LLC acquired a new stake in shares of ANI Pharmaceuticals during the fourth quarter worth $200,000. Institutional investors own 76.05% of the company's stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.